The extensive study of AAV vectors as carriers of gene therapy products has advanced the field from a promising new therapeutic concept into today's medical reality.
The use of bioassays facilitates the vector potency or
determination of neutralizing antibodies (NAbs).
We present a platform based on the reporter gene assay format that allows us to determine and titrate the presence of NAbs
against AAV vectors overnight.
This poster presents the proof of concept data for serotype-specific anti-NAbs detection.